- U.S. Patent Office Presented with Documentation Including 15 Prior Art
References Demonstrating Patent Invalidity -
WOBURN, Mass., Aug. 15 /PRNewswire/ -- VisEn Medical, Inc. today filed an inter partes re-examination request with the U.S. Patent and Trademark Office (USPTO) to invalidate and revoke claims of the Caliper Life Sciences (Nasdaq: CALP) patent US 7,255,851, which issued yesterday. VisEn initiated this action as part of its mission to enable leading research, pharmaceutical, and clinical institutions worldwide to develop, apply, and expand their use of fluorescence in vivo imaging from pre-clinical research through clinical medicine. As a basis for the filing, VisEn presented 15 published prior art references demonstrating the invalidity of the '851 patent, the majority of which had not been previously considered by the USPTO.
The claims in the Caliper (formerly Xenogen) '851 patent relate to
basic methods in optical in vivo imaging. However, prior to the July 1994
priority date of the '851 patent, numerous investigators worldwide had
researched, developed, and published on basic methods, as well as on
significant advances, in the field of optical in vivo imaging, including
the use of: (i) light- generating systems used to propagate light through
tissues; (ii) light- emitting molecules, conjugates, and entities used in
vivo to enhance image contrast and specificity; and (iii) instrumentation
and methods for the detection and images construction of the emitted light.
Collectively, this early research set the foundation for the further
development of the optical in vivo imaging technologies now utilized in the
fields of research, drug development and healthcare. This early publ
|SOURCE VisEn Medical, Inc.|
Copyright©2007 PR Newswire.